Frontotemporal Dementia, Behavioral Variant
10
3
3
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
20.0%
2 terminated out of 10 trials
66.7%
-19.9% vs benchmark
0%
0 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (10)
ECOCAPTURE for the Assessment of Apathy Under Real-life Conditions
Nabilone for Agitation in Frontotemporal Dementia
Links Between Self-awareness and Sociocognitive Processes in Neurodegenerative Diseases
Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia
Voices Of Individuals: Challenges and Experiences Of bvFTD
Understanding Mechanisms of Synaptic Degeneration Underlying Clinical Symptoms in Patients With MDs and NDs.
Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia
A Study of the Behavioral Variant of Frontotemporal Dementia and Bipolar Disorder: a Neuroimaging and Epigenetics Integrated Approach
Intranasal Insulin in Frontotemporal Dementia (FTD)
Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia